Shanghai, China, October 21, 2024 – Asieris Pharmaceuticals (688176.SH), a leading global biopharmaceutical company dedicated to advancing innovative therapies for genitourinary tumors and women health with significant unmet medical needs, announces the immediate appointment of Mr. Richard Zhao as Senior Vice President of Business Development. Richard will report directly to Dr. Kevin Pan, Founder, Chairman and CEO of Asieris Pharmaceuticals.
Mr. Richard Zhao, Senior Vice President of Business Development, Asieris Pharmaceuticals
In his new role at Asieris, Richard will be responsible for formulating and executing business development strategies that align with the company’s overall strategic goals. He will focus on building an extensive industry cooperation network and leading deal transactions such as in-licensing, joint R&D, commercialization partnerships, M&A and joint ventures, with a strong emphasis on the company’s global growth.
With over two decades of experience in the pharmaceutical industry, Richard has an extensive background in healthcare investment and business collaborations. He has excelled in strategic planning, business development, cross-border mergers and acquisitions ，and product launches & lifecycle management.. Before joining Asieris Pharmaceuticals, Richard served as Senior Vice President and Head of Business Development at CanSino Bio, where he drove significant business growth through strategic partnerships and mergers. He played a crucial role in the collaboration agreement between CanSino Bio and AstraZeneca for an mRNA vaccine. Prior to that, Richard led key licensing, investment, and M&A transactions at Frontier Biotech, Tasly Holding Group, Fosun Pharma, and Bayer, including the acquisition of Breas Medical Group by Fosun Pharma. He also served as International Market Director for the Radiology and Imaging division at Bayer’s US operations.
“We are delighted to welcome Richard to Asieris，further bolstering our business development capabilities,”said Dr. Kevin Pan.”Richard brings sharp industry insights and a proven track record in M&A, licensing, and external collaborations across both pharmaceutical and medical device sectors. His expertise and leadership will be crucial in advancing our goal to become a leading player in the genitourinary field and deliver integrated solutions from diagnosis to treatment for patients worldwide.”
Richard expressed his enthusiasm about joining Asieris, stating, “I am thrilled to join Asieris, a global innovative drug company. Asieris’ global expansion capabilities, innovative R&D pipeline, and cutting-edge technology platform impress me deeply. I look forward to working with Asieris’ excellent team to accelerate the company’s business development and bring innovative therapies to benefit more patients sooner.”
Richard holds a Bachelor of Arts degree from Shanghai International Studies University, a Master of Business Administration degree from China Europe International Business School (CEIBS), and a Certificate of Professional Development from The Wharton School of the University of Pennsylvania.
About Asieris
Founded in March 2010, Asieris Pharmaceuticals (688176.SH) is a global biopharma company specializing in discovering, developing, and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases. We strive to improve human health and help people live more dignified lives. We aim to become a global pharma leader that integrates R&D, manufacturing, and commercialization in our areas of focus, as we provide best-in-class integrated diagnosis and treatment solutions for patients in China and worldwide.
The company has been developing its proprietary R&D platform and core technologies, exploring new mechanisms of action, and efficiently screening and evaluating drug candidates. With a well-established in-house R&D system and expertise in global drug development, Asieris is committed to launching first-in-class drugs and other innovative products to address huge unmet needs in its areas of focus.
Asieris is also enhancing its pipeline for genitourinary diseases via proprietary R&D and strategic partnerships, while closely following cutting-edge technologies and therapeutics. The company strives to discover and identify unmet clinical needs, and adopts a forward-looking approach to product planning and life-cycle management. We aim to establish an outstanding portfolio that covers diagnosis and treatment in a bid to benefit more patients in China and globally. Visit us at asieris.com
